Accessibility Menu
Cipher Pharmaceuticals logo

Cipher Pharmaceuticals(TSX) CPH

Market CapCA$369.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+293%
5 Year+596%
1 Year-7%
1 Month-14%
CA$14.39
-1.03%
-0.15Today
Cipher Pharmaceuticals last closing stock price
MetricPriceDate
Last closeCAD 14.542026-09-02
Cipher Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.12%CAD 14.102026-08-26
1 month-13.61%CAD 16.832026-07-31
3 month-13.19%CAD 16.752026-06-04
Year to date-3.45%CAD 15.062025-12-31
1 year-7.27%CAD 15.682025-09-02
3 year+266.25%CAD 3.972023-09-01
5 year+595.69%CAD 2.092021-09-03
Since inception+292.97%CAD 3.702004-02-25

Cipher Pharmaceuticals Financials at a Glance

Market Cap

CA$369.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$49.29M

Net Income (TTM)

$28.99M

EPS (TTM)

CA$1.55

P/E Ratio

9.17

Dividend

CA$0.00

Beta (Volatility)

0.42 (Low)

Price

CA$14.39

Volume

31,498

Open

CA$14.55

Previous Close

CA$14.39

Daily Range

CA$14.39 - CA$14.67

52-Week Range

CA$12.48 - CA$20.56

Estimated Earnings Date

Nov 5, 2026

CPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. is a specialized pharmaceutical company based in Oakville, Canada, focused on developing and marketing a diverse range of therapeutic solutions. Established in 2000, the company offers products targeting various medical conditions, including severe acne, impetigo, and pain management.

Products and Services
  • Epuris, a treatment for severe acne
  • Ozenoxacin, targeting impetigo in adults and children
  • Actikerall, prescribed for actinic keratosis
Growth Outlook
  • Robust pipeline includes Trevyent for pulmonary arterial hypertension
  • CF-101 under investigation for severe plaque psoriasis
  • Potential market expansion with new product launches
Financial Highlights
  • Q2 2026 revenue of 11.76 million, showing consistent performance
  • Net income of 3.91 million in Q2 2026, reflecting strong profitability
  • TTM net profit margin of 58.81%, indicating efficient operations
Cipher Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry, with a market capitalization of approximately CAD 360 million. The company has demonstrated a solid financial performance, with a trailing twelve-month (TTM) net profit margin of 58.81%, showcasing its ability to convert revenue into profit effectively. The recent quarterly results indicate a revenue of 11.76 million for Q2 2026, alongside a net income of 3.91 million, reflecting the company's strong operational efficiency. The growth outlook remains promising, driven by a robust pipeline of products aimed at addressing unmet medical needs. Cipher's focus on innovative therapies positions it well for future expansion in the pharmaceutical market. With a low debt ratio and a strong cash flow, the company is well-equipped to navigate the competitive landscape and capitalize on new opportunities.
AI Generated • Aug 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

43

CEO

Craig Mull

Website

www.cipherpharma.com

Headquarters

Mississauga, ON L4W 0A9, CA

CPH Financials

Key Financial Metrics (TTM)

Gross Margin

70.55%

Operating Margin

38.75%

Net Income Margin

58.81%

Return on Equity

22.74%

Return on Capital

12.78%

Return on Assets

18.51%

Earnings Yield

10.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$369.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

25.42M

Volume

31.50K

Avg. Volume

32.87K

Financials (TTM)

Gross Profit

$34.78M

Operating Income

$19.10M

EBITDA

$24.42M

Operating Cash Flow

$27.05M

Capital Expenditure

-$122.94K

Free Cash Flow

$26.93M

Cash & ST Invst.

$9.10M

Total Debt

$366.40K

Cipher Pharmaceuticals Performance Analysis

Cipher Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 26,915,821-2.2%
20232023-12-31USD 28,562,0766.1%
20242024-12-31USD 45,706,02860.0%
20252025-12-31USD 70,494,60554.2%
Cipher Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.1%
Q42025-12-31-3.3%
Q12026-03-31-0.9%
Q22026-06-30-4.4%
Cipher Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.34270.8%
20232023-12-31USD 1.08-19.5%
20242024-12-31USD 0.63-42.1%
20252025-12-31USD 1.47134.3%
Cipher Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.5%
Q42025-12-31147.6%
Q12026-03-31-53.8%
Q22026-06-30-37.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$11.76M

-12.1%

Gross Profit

$7.71M

-29.2%

Gross Margin

65.58%

N/A

Market Cap

CA$369.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$73.91M

N/A

Employees

5

N/A

Net Income

$3.91M

-33.7%

EBITDA

$6.10M

-10.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$9.10M

-19.8%

Total Debt

$366.40K

-98.6%

Accounts Receivable

$12.12M

+2.1%

Inventory

$9.23M

+65.5%

Long Term Debt

$124.80K

-99.5%

Short Term Debt

$241.61K

-7.8%

Return on Assets

18.51%

N/A

Return on Invested Capital

13.93%

N/A

Free Cash Flow

$2.96M

-50.8%

Operating Cash Flow

$2.98M

-50.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACB.TOAurora Cannabis Inc.
CA$5.37-3.59%
NGEN.VNervGen Pharma Corp.
CA$5.15+3.00%
HITI.VHigh Tide Inc.
CA$3.45-0.29%
TSND.TOTerrAscend Corp.
CA$0.89-2.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.77-0.01%
HPEHewlett Packard Enterprise
$54.44+0.05%
FFord Motor Company
$14.41+0.02%
SNAPSnap
$5.70+0.02%

Questions About CPH

What is the current price of Cipher Pharmaceuticals?

Cipher Pharmaceuticals is trading at CA$14.39 per share.

What is the 52-week range for Cipher Pharmaceuticals?

Over the past 52 weeks, Cipher Pharmaceuticals has traded between CA$12.48 and CA$20.56.

How much debt does Cipher Pharmaceuticals have?

As of the most recent reporting period, Cipher Pharmaceuticals reported total debt of $520.68K.

How much cash does Cipher Pharmaceuticals have on hand?

Cipher Pharmaceuticals reported $12.93M in cash and cash equivalents in its most recent financial results.

What is Cipher Pharmaceuticals’s dividend yield?

Cipher Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services